The populations modelled in the submission were as follows: Indication 1: Patients with R/R CLL who had the del(17p)/TP53 aberration and whose disease had progressed after treatment with a BCRi; Indication 2: Patients with R/R CLL who lacked the del(17p)/TP53 aberration and whose disease had progressed after treatment with both chemoimmunotherapy and a BCRi. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.